Home > Boards > US Listed > Miscellaneous >

ReShape LifeSciences Inc. (RSLS)

RSLS RSS Feed
Add RSLS Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 1/7/2022 12:59:11 PM - Followers: 51 - Board type: Free - Posts Today: 0

ReShape Lifesciences™ 

https://www.reshapelifesciences.com/

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an FDA-approved pacemaker-like device called the ReShape vBloc System, is designed to help patients with a 40-45 kg/m2, or a 35-39.9 kg/m2 BMI and at least one co-morbidity feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

ReShape Lifesciences was incorporated in Minnesota in December 2002 under the name Beta Medical, Inc. In 2003, the Company changed its name to EnteroMedics Inc. and in 2004 reincorporated in Delaware. EnteroMedics began trading on the NASDAQ Stock Market on November 15, 2007.   The Company acquired ReShape Medical, Inc. in October 2017 and subsequently changed its name to ReShape Lifesciences, Inc. 

Financials http://ir.reshapelifesciences.com/static-files/cefa86e6-3998-4cb2-b8d8-c5447d7383b5

PART I – FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS RESHAPE LIFESCIENCES INC. Condensed Consolidated Balance Sheets (Unaudited) June 30, December 31, 2018 2017 ASSETS Current assets: Cash and cash equivalents $ 1,863,217 $ 10,163,208 Accounts receivable (net of allowance for bad debts of $228,165 and $155,872 at June 30, 2018 and December 31, 2017) 446,027 488,613 Inventory 2,101,017 2,817,112 Prepaid expenses and other current assets 919,543 467,783 Total current assets 5,329,804 13,936,716 Property and equipment, net 303,206 438,621 Goodwill — 27,186,620 Other intangible assets, net 44,802,230 46,152,577 Other assets 76,827 990,015 Total assets $ 50,512,067 $ 88,704,549 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 4,201,239 $ 1,088,271 Accrued expenses 4,499,875 5,955,518 Total current liabilities 8,701,114 7,043,789 Deferred income taxes 2,700,681 5,292,291 Common stock warrant liability 74 1,600 Total liabilities 11,401,869 12,337,680 Commitments and contingencies (Note 7) Stockholders’ equity: Preferred stock, 5,000,000 shares authorized: Series B convertible preferred stock, $0.01 par value; 20,000 shares issued and 2,957 and 6,055 shares outstanding at June 30, 2018 and December 31, 2017, respectively 30 61 Series C convertible preferred stock, $0.01 par value; 187,772 shares issued and 95,388 shares outstanding at June 30, 2018 and December 31, 2017 954 954 Series D convertible preferred stock, $0.01 par value; 6,000 shares issued and 4,750 and zero shares outstanding at June 30, 2018 and December 31, 2017 48 — Common stock, $0.01 par value; 275,000,000 shares authorized at June 30, 2018 and December 31, 2017; 3,610,009 and 2,063,808 shares issued and outstanding at June 30, 2018 and December 31, 2017 36,100 20,640 Additional paid-in capital 424,158,496 411,104,568 Accumulated deficit (385,085,430) (334,759,354) Total stockholders’ equity 39,110,198 76,366,869 Total liabilities and stockholders’ equity $ 50,512,067 $ 88,704,549 See accompanying notes to condensed consolidated financial statements.

RESHAPE LIFESCIENCES INC. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Product sales $ 633,554 $ 93,060 $ 1,574,985 $ 133,100 Other revenue 19,815 — 28,382 — Total revenue 653,369 93,060 1,603,367 133,100 Cost of revenue 634,774 54,472 1,463,731 83,995 Gross profit 18,595 38,588 139,636 49,105 Operating expenses: Selling, general and administrative 6,710,518 5,560,787 16,756,075 11,489,773 Research and development 2,439,337 1,352,075 5,126,856 2,476,488 Goodwill impairment 27,186,620 — 27,186,620 — Total operating expenses 36,336,475 6,912,862 49,069,551 13,966,261 Operating loss (36,317,880) (6,874,274) (48,929,915) (13,917,156) Other income (expense): Interest income 263 — 674 100 Interest expense — — (2,735) — Change in value of warrant liability 369 34,395 1,494 (288,735) Other, net (142,145) (298) (144,416) (1,198) Loss before income taxes (36,459,393) (6,840,177) (49,074,898) (14,206,989) Income tax benefit 1,208,560 — 2,590,613 — Net loss $ (35,250,833) $ (6,840,177) $ (46,484,285) $ (14,206,989) Adjustment for convertible preferred stock and warrants (3,841,790) — (3,841,790) — Net loss attributable to common shareholders (39,092,623) (6,840,177) (50,326,075) (14,206,989) Net loss per share—basic and diluted $ (15.78) $ (13.68) $ (22.14) $ (32.13) Shares used to compute basic and diluted net loss per share 2,477,910 500,114 2,273,160 442,191






The Company trades on the NASDAQ under the ticker symbol RSLS.http://ir.reshapelifesciences.com/financial-information/sec-filings



As of August 10, 2018, 9,013,421 shares of the registrant’s Common Stock were outstanding.

RSLS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RSLS News: ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update 04:30 AM
RSLS News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/13/2022 01:16:05 PM
RSLS News: Statement of Changes in Beneficial Ownership (4) 05/12/2022 12:07:21 PM
RSLS News: ReShape Lifesciences to Present at the Q2 Investor Summit 04/26/2022 04:30:00 AM
RSLS News: Current Report Filing (8-k) 04/14/2022 01:13:39 PM
News News Alert: ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update 05/16/2022 04:30:00 AM
PostSubject
#2538   Bottom? Grabbed some. scotsand 01/07/22 12:59:11 PM
#2537   Lets GO $RSLS Filterthenoise 01/03/22 08:21:56 PM
#2536   RSLS - Will Increase In Price Next Week Jake L 12/12/21 07:20:49 PM
#2535   Potential catalyst for RSLS this week: SmallCapStockGuy 12/12/21 02:43:08 PM
#2534   3.08 up 24% crudeoil24 10/08/21 09:58:09 AM
#2533   GANGBUSTERS!!!!! crudeoil24 10/08/21 09:43:28 AM
#2532   Here she blows!!!! G-lupo 08/18/21 10:18:13 AM
#2531   Shorty you are going to get crushed trendzone 07/21/21 04:02:56 PM
#2530   Low float biotech piece of garbage- so manipulated antman 07/12/21 10:22:35 AM
#2529   And then it gets flush out pos imo?? Roadtojourney 07/09/21 03:45:56 PM
#2528   Looks bottomy! Filterthenoise 07/09/21 10:27:41 AM
#2527   $RSLS is continuing for the top for the AlphaStockNews 07/09/21 07:48:35 AM
#2526   RSLS - WALLSTREETBETS Watchlist Jake L 07/08/21 08:48:11 PM
#2525   Don't believe she'll fall this day appreciably after hours! armstjo1 07/08/21 02:58:07 PM
#2524   Nice. It will be back roaring Filterthenoise 06/29/21 05:00:01 PM
#2523   Sold after hours yesterday, 7.10. harr449 06/29/21 04:51:51 PM
#2522   Gap fill coming maybe? BTFD kinda day Filterthenoise 06/29/21 08:57:06 AM
#2521   Fell after hours. harr449 06/29/21 08:53:30 AM
#2520   Looks good here Filterthenoise 06/28/21 01:59:47 PM
#2519   Flippers taking profits today. harr449 06/28/21 01:49:36 PM
#2518   $RSLS is screaming for the top after an AlphaStockNews 06/28/21 08:03:51 AM
#2517   RSLS$ $15 TARGET PRICE TODAY WOOHOOOOOOOOO weedtrader420 06/28/21 07:20:08 AM
#2516   RSLS 8.25 that poster was right! swampboots 06/28/21 07:19:46 AM
#2515   Yes- RSLS - Waking up large! antman 06/27/21 11:25:50 PM
#2514   $$$$$ 420man 06/27/21 04:35:49 PM
#2513   RSLS: this poster usually has a level head: swampboots 06/25/21 07:27:14 PM
#2512   RSLS can be 8! swampboots 06/25/21 04:41:05 PM
#2511   I can't believe there isn't any attention here QCAVN 06/23/21 10:51:42 AM
#2510   RSLS 6.21 if alogs off can low float swampboots 06/21/21 09:56:20 AM
#2509   My mistake....RSLS on Nasdaq submitted to ADMIN. Bygones, :-D Renee 06/20/21 12:36:37 PM
#2508   RSLS is on NASDAQ now... just sayin'(fka RSLS)? anyayzzz Crazy Money 06/19/21 11:54:35 AM
#2507   Must think like the eNemy, short algos are swampboots 06/17/21 04:58:25 PM
#2506   I have seen this happen to various 'tiny antman 06/17/21 04:44:54 PM
#2505   GRAY dr5ipped and dropped and then it did swampboots 06/17/21 03:56:20 PM
#2504   Why it keeps dropping and dropping antman 06/17/21 12:50:35 PM
#2503   RSLS 6.76 swampboots 06/16/21 08:00:56 PM
#2502   RSLS 6.50, may go down or crazy? swampboots 06/16/21 04:06:36 PM
#2501   RSLS 5.90 add to track with depth. swampboots 06/16/21 03:48:43 PM
#2500   On stocktwits all crying holding bag , but swampboots 06/16/21 02:27:32 PM
#2499   RSLS took some tracking shares 7.25 on drop swampboots 06/16/21 01:01:45 PM
#2498   I have no idea on that. Investors should Renee 06/16/21 09:03:03 AM
#2497   Renee:Rumor on stocktwits 2 days for trading shares swampboots 06/16/21 08:21:41 AM
#2496   RSLS: Business combination with Obalon Therapeutics Inc. (OBLN) Renee 06/15/21 08:39:17 PM
#2495   Nice movement this week Filterthenoise 05/28/21 04:33:42 PM
#2494   It's strange the other company it merged with crzzyduke 01/20/21 04:08:42 PM
#2493   200% up and still just me? Filterthenoise 01/20/21 01:37:54 PM
#2492   Happy New Year! Just me? Filterthenoise 12/31/20 11:14:47 PM
#2491   Quiet in here :) Filterthenoise 09/23/20 05:46:36 PM
#2490   strong buy BioSpecialist 01/24/20 03:13:33 PM
#2489   Sabby owns a few per this filing that michaeldouglas 01/21/20 02:41:39 PM
PostSubject
Consent Preferences